Primary Biliary Cholangitis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is an autoimmune, slowly progressive, liver disease resulting from the progressive destruction of the bile ducts in the liver. It is characterized by a triad of chronic cholestasis, circulating anti-mitochondrial antibodies (AMA), and characteristic liver biopsy findings of nonsuppurative destructive cholangitis and interlobular bile duct destruction.
The primary biliary cholangitis marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, late-to-mid-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for primary biliary cholangitis (PBU).
Leading Marketed Drugs for Primary Biliary Cholangitis
Some of the leading marketed drugs for primary biliary cholangitis are obeticholic acid, tauroursodeoxycholic acid, and Ursodiol (ursodeoxycholic acid).
Primary Biliary Cholangitis Marketed Drugs Segmentation by Mechanism of Action
The key mechanisms of action for primary biliary cholangitis marketed drugs are receptor agonist, enzyme inhibitor, receptor modulator, ion channel activator, and enzyme activator.
Primary Biliary Cholangitis Marketed Drugs Analysis, by Mechanism of Action
For more MoA insights into the primary biliary cholangitis marketed drugs, download a free report sample
Leading Pipeline Drugs for Primary Biliary Cholangitis
Some of the leading pipeline drugs of primary biliary cholangitis are saroglitazar, elafibranor, seladelpar lysine, setanaxib, bezafibrate SR, norursodeoxycholic acid, aldafermin, and RhuDex.
Primary Biliary Cholangitis Pipeline Drugs Segmentation by Mechanism of Action
The key mechanisms of action for primary biliary cholangitis pipeline drugs are receptor agonist, receptor antagonist, transporter inhibitor, enzyme inhibitor, and protein & peptide inhibitor.
Primary Biliary Cholangitis Pipeline Drugs Analysis, by Mechanisms of Action
For more MoA insights into the primary biliary cholangitis pipeline drugs, download a free report sample
Primary Biliary Cholangitis Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for primary biliary cholangitis pipeline drugs are oral and injection.
Primary Biliary Cholangitis Pipeline Drugs Analysis, by Routes of Administration
For more routes of administration insights into the primary biliary cholangitis pipeline drugs, download a free report sample
Primary Biliary Cholangitis Pipeline Drugs Segmentation by Molecule Type
The key molecule types for the primary biliary cholangitis pipeline drugs are small molecule, biologic, and oligonucleotide.
Primary Biliary Cholangitis Pipeline Drugs Analysis, by Molecule Types
For more molecule type insights into the primary biliary cholangitis pipeline drugs, download a free report sample
Top Sponsors in the Primary Biliary Cholangitis Marketed and Pipeline Drugs Market
Some of the top sponsors in the primary biliary cholangitis marketed and pipeline drugs market are Intercept Pharmaceuticals Inc, Genfit SA, CymaBay Therapeutics Inc, NGM Biopharmaceuticals Inc, Xjing Hospital, GSK Plc, Alexion Pharmaceuticals Inc, and GenKyoTex SA.
Primary Biliary Cholangitis Marketed Drugs Report Overview
Key Mechanisms of Action | Receptor Agonist, Enzyme Inhibitor, Receptor Modulator, Ion Channel Activator, and Enzyme Activator |
Primary Biliary Cholangitis Pipeline Drugs Report Overview
Key Mechanisms of Action | Receptor Agonist, Receptor Antagonist, Transporter Inhibitor, Enzyme Inhibitor, and Protein & Peptide Inhibitor |
Key Routes of Administration | Oral And Injection |
Key Molecule Types | Small Molecule, Biologic, and Oligonucleotide |
Top Sponsors (Marketed and Pipeline Drugs) | Intercept Pharmaceuticals Inc, Genfit SA, CymaBay Therapeutics Inc, NGM Biopharmaceuticals Inc, Xjing Hospital, GSK Plc, Alexion Pharmaceuticals Inc, and GenKyoTex SA. |
Scope
GlobalData’s Primary Biliary Cholangitis: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Primary Biliary Cholangitis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Primary Biliary Cholangitis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key mechanisms of action for primary biliary cholangitis marketed drugs?
The key mechanisms of action for primary biliary cholangitis marketed drugs are receptor agonist, enzyme inhibitor, receptor modulator, ion channel activator, and enzyme activator.
-
What are the key mechanisms of action for primary biliary cholangitis pipeline drugs?
The key mechanisms of action in the primary biliary cholangitis pipeline drugs market are receptor agonist, receptor antagonist, transporter inhibitor, enzyme inhibitor, and protein & peptide inhibitor.
-
What are the key routes of administration for primary biliary cholangitis pipeline drugs?
The key routes of administration in the primary biliary cholangitis pipeline drugs market are oral and injection.
-
What are the key molecule types for primary biliary cholangitis pipeline drugs?
The key molecule types in the primary biliary cholangitis pipeline drugs market are small molecule, biologic, and oligonucleotide.
-
Who are the top sponsors for the primary biliary cholangitis marketed and pipeline drugs market?
Some of the top sponsors in the primary biliary cholangitis marketed and pipeline drugs market are Intercept Pharmaceuticals Inc, Genfit SA, CymaBay Therapeutics Inc, NGM Biopharmaceuticals Inc, Xjing Hospital, GSK Plc, Alexion Pharmaceuticals Inc, and GenKyoTex SA.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.